arrow
S

Svein Oskar Frigstad

Vestre Viken Hospital Trust
H指数:15
被引数:1,632

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-related quality of life after diagnosis of ulcerative colitis and Crohn’s disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort)

溃疡性结肠炎和克罗恩病诊断后的健康相关生活质量:3年轨迹及与临床显著改善相关的因素(IBSEN III队列)

2026-10-140
OAAI
Environmental impact of computer-aided diagnosis in colonoscopy: a carbon footprint assessment of a prospective study cohort

计算机辅助诊断在结肠镜检查中的环境影响:一项前瞻性研究队列的碳足迹评估

ENDOSCOPY
IF12.8
2025-11-010
OA
Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort

粪便微生物组反映成人基于人群的起始队列中炎症性肠病的疾病状态和预后

2025-04-250
PRE
Fatigue trajectory and the impact of disease course through the first year after diagnosis in patients with Inflammatory Bowel Disease (the IBSEN III study)
2025-01-220
PRE
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study

早期克罗恩病的低手术率:来自前瞻性基于人群的起始队列研究——挪威东南部炎症性肠病III研究的结果

2024-12-011
OA
Fatigue in Patients with Inflammatory Bowel Disease in Remission One Year After Diagnosis (the IBSEN III Study)
2024-11-110
PRE
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
2024-06-042
OAAI
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
2023-06-055
OAAI
Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial
2021-03-0161
OAAI
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
2020-09-2318
OAAI
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
2019-04-1290
OAAI